<DOC>
	<DOCNO>NCT00650819</DOCNO>
	<brief_summary>This multicenter , randomize , double blind ; active-controlled parallel group study enrol subject primary hypercholesterolemia . Subjects receive ezetimibe , simvastatin , combination daily 8 week determine effect LDL-cholesterol .</brief_summary>
	<brief_title>Comparison Ezetimibe Plus Simvastatin Versus Ezetimibe Simvastatin Alone Subjects With Primary Hypercholesterolemia ( Study P03757 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Ezetimibe , Simvastatin Drug Combination</mesh_term>
	<criteria>Subjects must demonstrate willingness participate study comply procedure sign write informed consent . Subjects must &gt; = 18 year &lt; = 75 year age . Subjects Primary Hypercholesterolemia must finish Lab test list result must available time randomization Visit 3 ( Baseline Visit ) . LDLC concentration &gt; 3.64 mmol/L ( 140mg/dL ) &lt; = 6.3 mmol/L ( 250 mg/dL ) use Friedewald calculation Total cholesterol ( TC ) &gt; 5.2mmol/L ( 200mg/dL ) &lt; 12.7mmol/L ( 500mg/dL ) Triglyceride concentration &lt; = 3.99 mmol/L ( 350 mg/dL ) Liver transaminases ( ALT , AST ) must within normal limit , active liver disease CK &lt; 50 % upper limit normal Clinical laboratory test ( CBC , blood chemistry , urinalysis ) must within normal limit Subjects must report stable weight history least 4 week prior entry study Visit 3 ( Baseline Visit ) . Women childbearing potential ( include woman less 1 year postmenopausal woman become sexually active ) must use acceptable method birth control ( e.g . medically prescribed IUD , condom combination spermicide ) surgically sterilize ( e.g. , hysterectomy tubal ligation ) . Subjects must free clinically significant disease hyperlipidemia would interfere study evaluation . Subjects must understand able adhere dose visit schedule , must agree remain cholesterollowering diet duration study . Subjects whose body mass index ( BMI = weight [ kg ] /height2 [ ] ) &gt; = 30 Kg/m^2 Visit 3 ( Baseline Visit ) . Subjects know hypersensitivity HMGCoA reductase inhibitor . Subjects consume &gt; 14 alcoholic drink per week . ( A drink : beer , glass wine , single measure spirit ) . Any condition situation , opinion investigator , might pose risk subject interfere participation study . Women pregnant nursing Subjects observe designate washout period prohibit medication outline protocol Congestive heart failure define NYHA Class III IV . Uncontrolled cardiac arrhythmia . Myocardial infarction , coronary bypass surgery angioplasty within 6 month study entry . Unstable severe peripheral artery disease within 3 month study entry . Unstable angina pectoris within 6 month study entry . Uncontrolled hypertension ( treat untreated ) systolic blood pressure &gt; 160 mm Hg diastolic &gt; 100 mm Hg study entry . Uncontrolled ( determine HbA1c &gt; 7 % ) newly diagnose ( within 1month study entry ) diabetes mellitus . Uncontrolled endocrine metabolic disease know influence serum lipid lipoprotein , i.e. , secondary cause hyperlipidemia , secondary hypercholesterolemia due hypothyroidism ( TSH upper limit normal ) . Subjects history hypothyroidism stable therapy thyroid hormone replacement least 6 week eligible enrollment TSH level within normal limit enrollment . Known Impaired renal function ( plasma creatinine &gt; 2.0 mg/dL ) , nephrotic syndrome study entry . Disorders hematologic , digestive , central nervous system include cerebrovascular disease degenerative disease would limit study evaluation participation . Known HIV positive . Cancer within past 5 year ( except successfully treat basal squamous cell carcinoma ) . History mental instability , drug/alcohol abuse within past 5 year , major psychiatric illness adequately control stable pharmacotherapy . Subjects know coagulopathy ( PT PTT Visit 1 &gt; 1.25 time control ) Women receive hormonal therapy , include hormone replacement , estrogen antagonist/agonist , oral contraceptive . Any condition opinion investigator would make patient unsuitable enrollment , could interfere patient participate complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>